Amgen Reports Record $36.8 Billion Revenue in 2025 as Shares Surge 26%

Amgen CEO Bob Bradway released the 2025 annual letter to shareholders, highlighting a year of significant financial growth and strategic expansion. The biotechnology giant reported record total revenues of $36.8 billion for the year, driven by strong performance across its therapeutic portfolio. Investors responded positively to the company's trajectory, with Amgen's share price recording a substantial 26% increase during the period. Bradway emphasized that the company focused its investments on research, development, and manufacturing capabilities. These strategic allocations targeted key areas including general medicine, rare diseases, inflammation, and oncology. The report also underscored Amgen's growing footprint in the biosimilars market and its robust pipeline execution. Overall, the results reflect a strong corporate health that continues to bolster investor confidence in the healthcare sector.